FATTEN ELKOMY: Open Payments
NPI 1316388754 · COLUMBIA, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,175 in 55 payments from 11 companies in 2025. Trend: 2023 $682 · 2024 $757 · 2025 $1,175
Food & beverage: $1,056Education: $119
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 18 | $370 |
| Neurocrine BioSciences, Inc. | 7 | $232 |
| Otsuka America Pharmaceutical, Inc. | 8 | $148 |
| Alkermes, Inc. | 6 | $118 |
| E.R. Squibb & Sons, L.L.C. | 5 | $94 |
| ABBVIE INC. | 3 | $50 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Janssen Pharmaceuticals, Inc | 2 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $31 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
Products named: INGREZZA, UZEDY, AUSTEDO XR, ARISTADA, COBENFY, REXULTI, ABILIFY ASIMTUFII, VRAYLAR.
Industry payments across MO — which companies pay providers there.
